Showing results (261-270 of 426) with videos related to

Sort By:
Pageof 43
Breast Cancer Research and Treatment|December 3, 2013
Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expressionHisani N Horne, Mark E Sherman, Montserrat Garcia-Closas, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Nature Communications|September 4, 2024
Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utilityShadi Basyuni, Laura Heskin, Andrea Degasperi, et al.
Nature Communications|June 1, 2019
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Nature Communications|February 10, 2019
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapyJennifer L Caswell-Jin, Katherine McNamara, Johannes G Reiter, et al.
Cancer Cell|December 11, 2007
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed, Anthony D Mills, Ashraf E K Ibrahim, et al.
Breast Cancer Research : BCR|April 22, 2024
Clustering of HR + /HER2- breast cancer in an Asian cohort is driven by immune phenotypesJia-Wern Pan, Mohana Ragu, Wei-Qin Chan, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
British Journal of Cancer|May 23, 2019
A key genomic subtype associated with lymphovascular invasion in invasive breast cancerSasagu Kurozumi, Chitra Joseph, Sultan Sonbul, et al.
Breast Cancer Research : BCR|February 18, 2016
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancerH Raza Ali, Aliakbar Dariush, Elena Provenzano, et al.
Pageof 43